PepBank has 1 HGH fragment 176-191 study with results. It did not give HGH fragment 176-191. Data as of 2026-10-30.
Searches 0 results and 1 paper. Newer studies from Europe PMC
Identifiers, parent molecule, targets and development stage, from curated data.
The native 176-191 fragment contains the last 16 residues of mature human growth hormone. Its first residue is phenylalanine. AOD-9604 has tyrosine at the corresponding N terminus. It is a separate analogue. The related 177-191 fragment lacks Phe176. The query does not combine these product names.
No molecular target is recorded for this peptide.
Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.
16 amino acids · 1 disulfide bond
Calculated from the two sequences. Curated notes are shown as given.
16 of 16 aligned residues identical (100%) · Somatotropin (human growth hormone) 176–191
No differences in the aligned region.
Basis: Direct comparison with UniProt chain 27-217.
Calculated from the two sequences with @pepdb/chem alignToParent (ungapped unless a gap scores higher). The record’s curated notes are shown as given.
No formula or molecular weight is listed for HGH fragment 176-191.
@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses
pI 10.40 · Net charge at pH 7.4: 0.94
Point or use arrow keys
Henderson-Hasselbalch, EMBOSS pKa set, 1 disulfide. Calculated, not measured.
| pH | Net charge |
|---|---|
| 0 | 3.00 |
| 1 | 3.00 |
| 2 | 2.97 |
| 3 | 2.73 |
| 4 | 1.84 |
| 5 | 1.15 |
| 6 | 1.01 |
| 7 | 0.98 |
| 8 | 0.80 |
| 9 | 0.28 |
| 10 | 0.03 |
| 11 | −0.06 |
| 12 | −0.48 |
| 13 | −1.52 |
| 14 | −1.94 |
16 residues. Each residue counts in one class; F and W count as aromatic.
Loads the 3D viewer (3Dmol.js, about 150 KB) and the model file from AlphaFold DB (EMBL-EBI).
An ideal alpha-helix projection. It shows where the hydrophobic residues fall if the peptide folds as a helix. It does not show that it does.
Eisenberg consensus (normalized) scale · + K, R · − D, E
Assumes an ideal α-helix: 100° per residue, 3.6 residues per turn. The arrow is the mean hydrophobic moment (Eisenberg et al. 1984) and points at the hydrophobic face.
| Position | Residue | Angle | Eisenberg consensus (normalized) |
|---|---|---|---|
| 1 | F | 0° | 1.19 |
| 2 | L | 100° | 1.06 |
| 3 | R | 200° | -2.53 |
| 4 | I | 300° | 1.38 |
| 5 | V | 40° | 1.08 |
| 6 | Q | 140° | -0.85 |
| 7 | C | 240° | 0.29 |
| 8 | R | 340° | -2.53 |
| 9 | S | 80° | -0.18 |
| 10 | V | 180° | 1.08 |
| 11 | E | 280° | -0.74 |
| 12 | G | 20° | 0.48 |
| 13 | S | 120° | -0.18 |
| 14 | C | 220° | 0.29 |
| 15 | G | 320° | 0.48 |
| 16 | F | 60° | 1.19 |
People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.
PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.
Counts are exact and come from studies that gave the peptide.
Studies by year
1 of 1 study has results (100%), published 2022. Top row: every study. Bottom row: studies with results about HGH fragment 176-191, by class. The rows use different scales.
Studies1 in all, 2022
Studies with results1 in all, 2022
Retracted studies are left out. A study with results in two classes counts in both.
AI wrote and checked these results. AI can make mistakes, so check important results against the source.
Registered trials that test the peptide, with phase, status and dates. A dot marks trials with posted results.
0 trials match. Highest phase first. Data from ClinicalTrials.gov.
No trial matches these filters.
Studies on this peptide. Some have results. The others have none yet.
1 study matches. Retracted studies are left out.
Showing 1 of 1 studyquery qry_a0d4f267873c528c20c9be40
1 study
Not a test of HGH fragment 176-191 alone · 2022
Habibullah et al. 2022Drug design, development and therapycited by 8
PMID 35783198PMC9249349DOI 10.2147/dddt.s367586PUB-35783198
Page 1 of 1
Habibullah MM · Drug design, development and therapy · 2022
Not a test of HGH fragment 176-191 alone · 2 results
Approval and sport status, and the safety outcomes reported in study results. Laws and labels change, so check the regulator for the current status.
| Jurisdiction | Body | Status | As of | Source |
|---|---|---|---|---|
| US | FDA | The Drugs@FDA API returned no matching active ingredient for HGH FRAGMENT, 176-191, AOD-9604 or AOD9604. This name search does not prove worldwide absence. | 13 Oct 2026 | api.fda.gov (opens in a new tab) |
| EU | EMA | No matching active substance in the EMA central medicines data file. National authorisations are not covered. | 13 Oct 2026 | ema.europa.eu (opens in a new tab) |
| Sport | WADA | Banned in sport (WADA S2.2.3) Growth hormone fragments are prohibited at all times. | 2026 List | wada-ama.org (opens in a new tab) |
| Russia | Note | National medicine registration not established in this profile. | 13 Oct 2026 | Not recorded |
Reported effects from study results.
No study results yet
The doses that these studies used. They are not recommendations.
No dose was reported in the study results.
PepBank is a research reference. Talk to a doctor before you use any peptide.
Data version, change history and code for this peptide.
curl -s https://Evidence summary for HGH fragment 176-191: counts by class, key results with sources, notices, data version.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Top outcomes
Outcome groups with study results, by evidence class.
No study results yet
Data version 308560. Bar length is the number of results, not the size of an effect.
Evidence matrix
Study results by outcome and evidence class. Arrows show how the measured outcome moved, not whether the change is good.
No study results yet
Data version 308560. Shade grows with the number of results. Every cell shows the exact count.